Adam Enver Frampton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3062003/publications.pdf

Version: 2024-02-01

115 papers 3,036 citations

32 h-index 50 g-index

116 all docs

 $\begin{array}{c} 116 \\ \\ \text{docs citations} \end{array}$

times ranked

116

5557 citing authors

#	Article	IF	CITATIONS
1	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology, 2014, 146, 268-277.e18.	1.3	141
2	MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors. PLoS ONE, 2012, 7, e32068.	2.5	122
3	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget, 2018, 9, 19006-19013.	1.8	116
4	miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Research, 2013, 41, 5400-5412.	14.5	111
5	TGF- \hat{l}^2 induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications, 2018, 9, 1845.	12.8	101
6	miRâ€515â€5p controls cancer cell migration through <scp>MARK</scp> 4 regulation. EMBO Reports, 2016, 17, 570-584.	4.5	97
7	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	2.8	94
8	Radio-frequency-assisted Liver Partition With Portal Vein Ligation (RALPP) for Liver Regeneration. Annals of Surgery, 2015, 261, e45-e46.	4.2	89
9	Gene of the month: E-cadherin (<i>CDH1</i>). Journal of Clinical Pathology, 2013, 66, 928-932.	2.0	82
10	Reduced Dissemination of Circulating Tumor Cells With No-Touch Isolation Surgical Technique in Patients With Pancreatic Cancer. JAMA Surgery, 2014, 149, 482.	4.3	81
11	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2016, 16, 14-27.	1.1	81
12	Downregulation of microRNA-515-5p by the Estrogen Receptor Modulates Sphingosine Kinase 1 and Breast Cancer Cell Proliferation. Cancer Research, 2013, 73, 5936-5948.	0.9	71
13	Growth Arrest-Specific Transcript 5 Associated snoRNA Levels Are Related to p53 Expression and DNA Damage in Colorectal Cancer. PLoS ONE, 2014, 9, e98561.	2.5	66
14	Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. American Journal of Pathology, 2019, 189, 71-81.	3.8	59
15	miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 384-393.	1.1	58
16	Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1063-1071.	2.5	56
17	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet, The, 2015, 385, S37.	13.7	54
18	MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocrine-Related Cancer, 2016, 23, 711-726.	3.1	54

#	Article	IF	Citations
19	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncology, 2013, 9, 1923-1935.	2.4	53
20	TP53 regulates miRNA association with AGO2 to remodel the miRNA–mRNA interaction network. Genome Research, 2016, 26, 331-341.	5.5	51
21	Tumor Infiltration in the Medial Resection Margin Predicts Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 1875-1882.	1.7	50
22	Gene of the month: HGF. Journal of Clinical Pathology, 2016, 69, 575-579.	2.0	47
23	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2020, 271, 1137-1147.	4.2	47
24	Surgical treatment for liver cancer. World Journal of Gastroenterology, 2010, 16, 927.	3.3	46
25	miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics, 2017, 18, 1343-1358.	1.3	45
26	Two-Stage Resection for Bilobar Colorectal Liver Metastases: RO Resection Is the Key. Annals of Surgical Oncology, 2011, 18, 1939-1946.	1.5	44
27	Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer. BioMed Research International, 2014, 2014, 1-17.	1.9	42
28	The Clinico-Pathologic Role of MicroRNAs miR-9 and miR-151-5p in Breast Cancer Metastasis. Molecular Diagnosis and Therapy, 2012, 16, 167-172.	3.8	40
29	Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2016, 23, 3709-3717.	1.5	38
30	Loss of miR-126 is crucial to pancreatic cancer progression. Expert Review of Anticancer Therapy, 2012, 12, 881-884.	2.4	36
31	Gene of the month: lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 2021, 74, 543-547.	2.0	35
32	Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Research and Treatment, 2015, 149, 59-67.	2.5	34
33	Rapid Induction of Liver Regeneration for Major Hepatectomy (REBIRTH): A Randomized Controlled Trial of Portal Vein Embolisation versus ALPPS Assisted with Radiofrequency. Cancers, 2019, 11, 302.	3.7	34
34	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. PLoS ONE, 2013, 8, e62543.	2.5	32
35	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin \hat{l}^2 ₁ . Science Signaling, 2014, 7, ra58.	3.6	32
36	A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics, 2014, 14, 267-271.	3.1	29

#	Article	IF	Citations
37	The p53 miRNA interactome and its potential role in the cancer clinic. Epigenomics, 2013, 5, 417-428.	2.1	27
38	Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1525-1529.	3.1	25
39	A systematic review of gallstone sigmoid ileus management. Annals of Medicine and Surgery, 2018, 27, 32-39.	1.1	25
40	microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Review of Anticancer Therapy, $2011, 11, 1837-1842$.	2.4	23
41	Towards a clinical use of miRNAs in pancreatic cancer biopsies. Expert Review of Molecular Diagnostics, 2013, 13, 31-34.	3.1	23
42	The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA–mRNA interaction network. Lancet, The, 2015, 385, S15.	13.7	23
43	Size-Exclusion Chromatography as a Technique for the Investigation of Novel Extracellular Vesicles in Cancer. Cancers, 2020, 12, 3156.	3.7	23
44	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. Clinical Epigenetics, 2015, 7, 129.	4.1	22
45	The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. Cancers, 2020, 12, 3250.	3.7	22
46	"Open Sesame?― Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers, 2020, 12, 3206.	3.7	21
47	Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Review of Molecular Diagnostics, 2013, 13, 425-430.	3.1	20
48	Pharmacogenetics of treatments for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 437-447.	3.3	20
49	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors. Annals of Surgery, 2021, 274, e1-e9.	4.2	20
50	Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas. Cancers, 2021, 13, 66.	3.7	20
51	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 2016, 7, 28556-28569.	1.8	19
52	The density of mast cells c-Kit+ and tryptase+ correlates with each other and with angiogenesis in pancreatic cancer patients. Oncotarget, 2017, 8, 70463-70471.	1.8	18
53	Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Hpb, 2021, 23, 1656-1665.	0.3	16
54	Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer. Expert Review of Molecular Diagnostics, 2013, 13, 141-145.	3.1	15

#	Article	IF	CITATIONS
55	Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR. Nucleic Acids Research, 2017, 45, gkx022.	14.5	15
56	miRNAs in breast cancer: ready for real time?. Pharmacogenomics, 2012, 13, 709-719.	1.3	14
57	Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers. Expert Review of Anticancer Therapy, 2013, 13, 21-27.	2.4	14
58	A systematic review of symptomatic small bowel lipomas of the jejunum and ileum. Annals of Medicine and Surgery, 2020, 58, 52-67.	1.1	14
59	Preoperative Superselective Mesenteric Angiography and Methylene Blue Injection for Localization of Obscure Gastrointestinal Bleeding. JAMA Surgery, 2013, 148, 665.	4.3	13
60	Gene of the month: <i>NANOG</i> . Journal of Clinical Pathology, 2015, 68, 763-765.	2.0	13
61	Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Expert Review of Molecular Diagnostics, 2016, 16, 733-736.	3.1	13
62	The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with highâ€dose chemotherapy as consolidation: a nonâ€cisplatinâ€based induction approach. BJU International, 2016, 117, 418-423.	2.5	13
63	A New Combination Immunotherapy in Advanced Melanoma. New England Journal of Medicine, 2022, 386, 91-92.	27.0	13
64	Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Review of Molecular Diagnostics, 2013, 13, 325-329.	3.1	11
65	Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker?. Expert Review of Molecular Diagnostics, 2013, 13, 793-796.	3.1	11
66	Activating mutations of <i>GNAS </i> and <i> KRAS </i> in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas. Expert Review of Molecular Diagnostics, 2015, 15, 325-328.	3.1	11
67	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	12.1	11
68	A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 1020.	3.7	10
69	18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. Nuclear Medicine and Biology, 2012, 39, 982-985.	0.6	9
70	Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1155-1162.	3.1	9
71	A systematic review into patient reported outcomes following pancreaticoduodenectomy for malignancy. European Journal of Surgical Oncology, 2021, 47, 970-978.	1.0	9
72	Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Journal of Clinical Pathology, 2022, 75, 217-221.	2.0	9

#	Article	lF	CITATIONS
73	Determination of cut-offs for circulating tumor cell measurement in metastatic cancer. Expert Review of Anticancer Therapy, 2011, 11, 1345-1350.	2.4	8
74	Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma. Expert Review of Gastroenterology and Hepatology, 2014, 8, 241-246.	3.0	8
75	Single-cell sequencing in cancer research. Expert Review of Molecular Diagnostics, 2016, 16, 1-5.	3.1	8
76	Are we following an algorithm for managing chronic anal fissure? A completed audit cycle. Annals of Medicine and Surgery, 2016, 5, 38-44.	1.1	8
77	The Clinical Significance of Transfer RNAs Present in Extracellular Vesicles. International Journal of Molecular Sciences, 2022, 23, 3692.	4.1	8
78	Use of the femoral artery route for placement of temporary catheters for emergency haemodialysis when all usual central venous access sites are exhausted. Nephrology Dialysis Transplantation, 2008, 24, 913-918.	0.7	7
79	The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. Surgery, 2012, 152, 936-938.	1.9	7
80	Is there a â€~margin' for error in pancreatic cancer surgery?. Future Oncology, 2013, 9, 31-34.	2.4	7
81	Challenges facingin vivotracking of mesenchymal stem cells used for tissue regeneration. Expert Review of Medical Devices, 2014, 11, 9-13.	2.8	7
82	miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia. Annals of Surgery, 2015, 262, e61-e62.	4.2	7
83	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. Journal of Cellular Physiology, 2020, 235, 8085-8097.	4.1	7
84	A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. International Journal of Medical Sciences, 2021, 18, 2166-2175.	2.5	7
85	Circulating molecular markers in pancreatic cancer: ready for clinical use?. Future Oncology, 2013, 9, 141-144.	2.4	6
86	Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?. Oncotarget, 2019, 10, 696-706.	1.8	6
87	Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?. Future Oncology, 2013, 9, 1861-1869.	2.4	5
88	Lymph node ratio can further stratify prognosis in subpopulations of breast cancer patients with axillary nodal metastases. Future Oncology, 2013, 9, 1425-1431.	2.4	5
89	Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 855-863.	3.0	5
90	En bloc resection of the pancreatic head and second part of duodenum for a duodenal gastrointestinal stromal tumor: a multi-media report. JOP: Journal of the Pancreas, 2010, 11, 396-400.	1.5	5

#	Article	lF	Citations
91	Biological vascular grafts for hemodialysis access. Expert Review of Medical Devices, 2013, 10, 171-175.	2.8	4
92	Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. Gut, 2020, 69, 404-405.	12.1	4
93	Simultaneous resection of synchronous colorectal liver metastases: a promising alternative to staged resections. Hepatobiliary Surgery and Nutrition, 2021, 10, 720-723.	1.5	4
94	The Role of a Vascular Access Surgeon in Ventriculo-Venous Shunts in Difficult Hydrocephalus. Journal of Vascular Access, 2010, 11, 150-154.	0.9	3
95	Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?. Pharmacogenomics, 2012, 13, 977-979.	1.3	3
96	Integrated analysis of miRNA and mRNA profiles enables target acquisition in human cancers. Expert Review of Anticancer Therapy, 2012, 12, 323-330.	2.4	3
97	Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Review of Anticancer Therapy, 2012, 12, 1275-1278.	2.4	3
98	Retinoblastoma protein determines aggressiveness in triple-negative breast cancer. Expert Review of Anticancer Therapy, 2012, 12, 581-584.	2.4	3
99	Serum miR-1290 as a Marker of Pancreatic Cancerâ€"Letter. Clinical Cancer Research, 2013, 19, 5250-5251.	7.0	3
100	Role of miRNAs in the response to anticancer therapy. Pharmacogenomics, 2012, 13, 1663-1666.	1.3	2
101	Optimizing Unresectable Colorectal Liver Metastases for Surgeryâ€"No Limits, Any Benefits?. Journal of Gastrointestinal Surgery, 2013, 17, 2185-2187.	1.7	2
102	Is there an optimal interventional device for the salvage of thrombosed native angioaccess for hemodialysis?. Expert Review of Medical Devices, 2013, 10, 27-31.	2.8	2
103	Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. American Journal of Gastroenterology, 2015, 110, 768-769.	0.4	2
104	Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma. Gut, 2022, 71, 1935-1936.	12.1	2
105	Is there a role for intravenous iron therapy in patients undergoing colorectal cancer resection?. Expert Review of Anticancer Therapy, 2012, 12, 1407-1412.	2.4	1
106	Cancer vaccines: is prevention better than cure?. Future Oncology, 2012, 8, 899-901.	2.4	1
107	The "Malignant Truth―About the Recurrence of Pancreatic Intraductal Papillary Mucinous Neoplasms. Archives of Surgery, 2012, 147, 977.	2.2	1
108	Do miRNAs hold the key to controlling EBV-driven tumorigenesis?. Future Virology, 2012, 7, 1045-1049.	1.8	1

#	Article	IF	CITATIONS
109	Raising a glass of red wine against cancer, or not?. Lancet Oncology, The, 2012, 13, 669-670.	10.7	1
110	Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma. Lancet, The, 2017, 389, S68.	13.7	1
111	Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?. Expert Review of Molecular Diagnostics, 2019, 19, 553-558.	3.1	1
112	Left hepatic trisectionectomy for hepatobiliary malignancies: Its' role and outcomes. A retrospective cohort study. Annals of Medicine and Surgery, 2020, 51, 11-16.	1.1	1
113	Research Highlights: Highlights from the latest articles in breast cancer pharmacogenomics. Pharmacogenomics, 2012, 13, 645-649.	1.3	O
114	Individualizing hemodynamic optimization during the management of circulatory collapse. Expert Review of Cardiovascular Therapy, 2012, 10, 1217-1220.	1.5	0
115	Integrating the Evidence for Single-incision Laparoscopic Cholecystectomy. Annals of Surgery, 2015, 261, e85-e87.	4.2	0